These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12975334)

  • 1. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
    Ohe T; Sato M; Tanaka S; Fujino N; Hata M; Shibata Y; Kanatani A; Fukami T; Yamazaki M; Chiba M; Ishii Y
    Drug Metab Dispos; 2003 Oct; 31(10):1251-4. PubMed ID: 12975334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
    Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
    Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
    Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
    Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
    He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
    Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
    Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
    Caruso A; Alvarez-Sánchez R; Hillebrecht A; Poirier A; Schuler F; Lavé T; Funk C; Belli S
    Biochem Pharmacol; 2013 Jun; 85(11):1684-99. PubMed ID: 23454189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
    Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
    Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
    Hsiao P; Bui T; Ho RJ; Unadkat JD
    Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Gnoth MJ; Sandmann S; Engel K; Radtke M
    Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.
    Washington CB; Wiltshire HR; Man M; Moy T; Harris SR; Worth E; Weigl P; Liang Z; Hall D; Marriott L; Blaschke TF
    Drug Metab Dispos; 2000 Sep; 28(9):1058-62. PubMed ID: 10950849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
    Zong J; Pollack GM
    J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
    Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
    Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
    J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
    Varma MV; Sateesh K; Panchagnula R
    Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
    Liu X; Cheong J; Ding X; Deshmukh G
    Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
    Fridén M; Winiwarter S; Jerndal G; Bengtsson O; Wan H; Bredberg U; Hammarlund-Udenaes M; Antonsson M
    J Med Chem; 2009 Oct; 52(20):6233-43. PubMed ID: 19764786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
    Panchagnula R; Bansal T; Varma MV; Kaul CL
    Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
    Kalvass JC; Olson ER; Pollack GM
    Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro.
    Yang ZH; Liu XD
    Epilepsy Res; 2008 Jan; 78(1):40-9. PubMed ID: 18063342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.